Ureter cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm involving the ureter
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Ureter cancer
- Therapeutic area
- Oncology
- ureter cancer
- cancer of ureter
- malignant neoplasm of the ureter
- malignant neoplasm of ureter
- malignant tumor of the ureter
- malignant tumor of ureter
- malignant tumour of the ureter
- malignant ureter neoplasm
- malignant ureter tumor
- malignant ureter tumour
- malignant ureteral neoplasm
- malignant ureteral tumor
- malignant ureteral tumour
- Severity
- Severe
- Nephrology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0008627
- Parent condition
- MONDO:0006295
Related records
Broader conditions (13)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Malignant urinary system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Ureter neoplasm
- Ureteral disorder
- Urinary system disorder
- Urinary system neoplasm
Narrower conditions (10)
- Carcinoma in situ of ureter
- Infiltrating ureter transitional cell carcinoma
- Regional ureteric cancer
- Ureter adenocarcinoma
- Ureter carcinoma
- Ureter small cell carcinoma
- Ureter squamous cell carcinoma
- Ureter transitional cell carcinoma
- Ureteral lymphoma
- Ureteric orifice cancer
Trials (95)
- A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
- A Genotype-Phenotype Urothelial Cancer Registry
- A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
- A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
- Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
- Afatinib in Advanced Refractory Urothelial Cancer
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- ARID1A and/or KDM6A Mutation and CXCL13 Expression
- Arsenic Trioxide in Treating Patients With Urothelial Cancer
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Drugs in development (6)
- Arsenic trioxide Phase 2
- Bortezomib Phase 2
- Carboplatin Phase 2
- Enfortumab vedotin Phase 2
- Gemcitabine hydrochloride Phase 2
- Vandetanib Phase 2